Pressure Biosciences Inc (PBIO) financial statements (2022 and earlier)

Company profile

Business Address 14 NORFOLK AVENUE
SOUTH EASTON, MA 02375
State of Incorp. MA
Fiscal Year End December 31
SIC 3826 - Laboratory Analytical Instruments (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments664475119954132
Cash and cash equivalents664475119954132
Receivables5396305041311,132653121
Inventory, net of allowances, customer advances and progress billings796492559593516615656
Inventory796492559593516615656
Other undisclosed current assets621219272315160193204
Total current assets:2,6201,3881,3861,0571,9021,5011,012
Noncurrent Assets
Operating lease, right-of-use asset173190206221214159
Property, plant and equipment271516192632
Long-term investments and receivables113275409517503363166
Long-term investments113275409517503363166
Intangible assets, net (including goodwill)425447469490512534555
Intangible assets, net (excluding goodwill)425447469490512534555
Total noncurrent assets:7149191,0991,2451,055963813
TOTAL ASSETS:3,3332,3072,4852,3032,9572,4651,825
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,5823,2133,2883,2278,7868,1456,732
Accounts payable418629711772706810870
Accrued liabilities2,0222,1642,1162,0382,0351,8661,681
Employee-related liabilities142421460418451392415
Interest and dividends payable    5,5945,0773,766
Deferred revenue44494247483729
Debt12,83112,27311,2658,6817,9825278,533
Due to related parties381851811661059090
Other liabilities7,1088,1657,4906,331   
Other undisclosed current liabilities71696765217,31559
Total current liabilities:22,67523,95422,33418,51816,94116,11415,443
Noncurrent Liabilities
Long-term debt and lease obligation102121139156527  
Long-term debt, excluding current maturities    527  
Operating lease, liability102121139156   
Liabilities, other than long-term debt971219263542
Deferred revenue971219263542
Other undisclosed noncurrent liabilities527527527527 527 
Total noncurrent liabilities:63865567870355356342
Total liabilities:23,31324,61023,01219,22017,49416,67715,485
Stockholders' equity
Stockholders' equity attributable to parent, including:(19,979)(22,303)(20,527)(16,918)(14,536)(14,212)(13,660)
Common stock83635342383227
Additional paid in capital62,30855,31852,86050,31349,07947,41445,120
Accumulated deficit(113,979)(108,596)(103,447)(96,466)(91,862)(88,187)(83,221)
Warrants and rights outstanding31,60830,91130,00529,19228,20726,52824,413
Other undisclosed stockholders' equity attributable to parent1111111
Total stockholders' equity:(19,979)(22,303)(20,527)(16,918)(14,536)(14,212)(13,660)
TOTAL LIABILITIES AND EQUITY:3,3332,3072,4852,3032,9572,4651,825

Income statement (P&L) ($ in thousands)

9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
Revenues518609560165534268254
Cost of revenue
(Cost of Goods and Services Sold)
(258)(287)(226)(26)(247)(135)(175)
Gross profit:26032233413928713379
Operating expenses(1,503)(969)(1,409)(623)(1,353)(1,599)(1,649)
Other undisclosed operating income (loss)   (557)247135175
Operating loss:(1,243)(646)(1,075)(1,041)(819)(1,331)(1,395)
Nonoperating expense(3,709)(4,099)(5,502)(3,163)(2,460)(3,238)(2,559)
Debt instrument, convertible, beneficial conversion feature      409
Interest and debt expense(277)(498)(725)(8,678)(396)(1,725)(1,136)
Loss before gain (loss) on sale of properties:(5,228)(5,243)(7,303)(12,882)(3,675)(6,294)(5,090)
Other undisclosed net income   10,341   
Net loss:(5,228)(5,243)(7,303)(2,541)(3,675)(6,294)(5,090)
Other undisclosed net income (loss) attributable to parent277498725(1,663)3961,7251,136
Net loss attributable to parent:(4,951)(4,745)(6,578)(4,204)(3,279)(4,569)(3,954)
Preferred stock dividends and other adjustments(432)(404)(403)(399)(397)(397)(325)
Other undisclosed net loss available to common stockholders, basic(816) (58)(61)   
Net loss available to common stockholders, diluted:(6,199)(5,149)(7,039)(4,665)(3,676)(4,966)(4,278)

Comprehensive Income ($ in thousands)

9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
Net loss:(5,228)(5,243)(7,303)(2,541)(3,675)(6,294)(5,090)
Comprehensive loss, net of tax, attributable to parent:(5,228)(5,243)(7,303)(2,541)(3,675)(6,294)(5,090)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: